nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—ABCB1—colon cancer	0.384	1	CbGaD
Norethindrone—CYP3A7—Irinotecan—colon cancer	0.0548	0.109	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0548	0.109	CbGbCtD
Norethindrone—ALB—Irinotecan—colon cancer	0.0512	0.101	CbGbCtD
Norethindrone—ALB—Fluorouracil—colon cancer	0.0491	0.0974	CbGbCtD
Norethindrone—CYP3A7—Vincristine—colon cancer	0.0479	0.095	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.0479	0.095	CbGbCtD
Norethindrone—CYP3A5—Irinotecan—colon cancer	0.0411	0.0816	CbGbCtD
Norethindrone—CYP3A5—Vincristine—colon cancer	0.0359	0.0713	CbGbCtD
Norethindrone—ALB—Methotrexate—colon cancer	0.0271	0.0537	CbGbCtD
Norethindrone—ABCB1—Irinotecan—colon cancer	0.0268	0.0531	CbGbCtD
Norethindrone—ABCB1—Vincristine—colon cancer	0.0234	0.0464	CbGbCtD
Norethindrone—CYP3A4—Irinotecan—colon cancer	0.016	0.0318	CbGbCtD
Norethindrone—ABCB1—Methotrexate—colon cancer	0.0142	0.0281	CbGbCtD
Norethindrone—CYP3A4—Vincristine—colon cancer	0.014	0.0278	CbGbCtD
Norethindrone—Abortion spontaneous—Fluorouracil—colon cancer	0.00721	0.0717	CcSEcCtD
Norethindrone—Cerebral thrombosis—Methotrexate—colon cancer	0.00405	0.0403	CcSEcCtD
Norethindrone—Thromboembolic event—Irinotecan—colon cancer	0.00378	0.0376	CcSEcCtD
Norethindrone—Thromboembolic event—Capecitabine—colon cancer	0.00253	0.0252	CcSEcCtD
Norethindrone—Infertility—Methotrexate—colon cancer	0.00194	0.0193	CcSEcCtD
Norethindrone—Blindness—Vincristine—colon cancer	0.00189	0.0188	CcSEcCtD
Norethindrone—Cerebral haemorrhage—Vincristine—colon cancer	0.00189	0.0188	CcSEcCtD
Norethindrone—Thromboembolic event—Methotrexate—colon cancer	0.00188	0.0187	CcSEcCtD
Norethindrone—Gastrointestinal symptom NOS—Fluorouracil—colon cancer	0.00166	0.0165	CcSEcCtD
Norethindrone—Embolism—Irinotecan—colon cancer	0.00159	0.0158	CcSEcCtD
Norethindrone—Abdominal cramps—Vincristine—colon cancer	0.00155	0.0154	CcSEcCtD
Norethindrone—Abdominal cramps—Irinotecan—colon cancer	0.00151	0.015	CcSEcCtD
Norethindrone—Prurigo—Capecitabine—colon cancer	0.00148	0.0147	CcSEcCtD
Norethindrone—Thrombosis—Irinotecan—colon cancer	0.00144	0.0143	CcSEcCtD
Norethindrone—Menorrhagia—Vincristine—colon cancer	0.00141	0.0141	CcSEcCtD
Norethindrone—Neoplasm malignant—Irinotecan—colon cancer	0.00119	0.0119	CcSEcCtD
Norethindrone—Hirsutism—Capecitabine—colon cancer	0.00117	0.0117	CcSEcCtD
Norethindrone—Deep vein thrombosis—Capecitabine—colon cancer	0.00112	0.0111	CcSEcCtD
Norethindrone—Tenderness—Fluorouracil—colon cancer	0.00112	0.0111	CcSEcCtD
Norethindrone—PGR—blood vessel—colon cancer	0.00111	0.106	CbGeAlD
Norethindrone—Embolism—Capecitabine—colon cancer	0.00106	0.0106	CcSEcCtD
Norethindrone—Pulmonary embolism—Irinotecan—colon cancer	0.00102	0.0101	CcSEcCtD
Norethindrone—Thrombosis—Capecitabine—colon cancer	0.000963	0.00958	CcSEcCtD
Norethindrone—ALB—gall bladder—colon cancer	0.00096	0.0911	CbGeAlD
Norethindrone—Metrorrhagia—Capecitabine—colon cancer	0.000955	0.00949	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Capecitabine—colon cancer	0.000921	0.00916	CcSEcCtD
Norethindrone—Thrombophlebitis—Irinotecan—colon cancer	0.000854	0.0085	CcSEcCtD
Norethindrone—Deep vein thrombosis—Methotrexate—colon cancer	0.000834	0.0083	CcSEcCtD
Norethindrone—Thrombophlebitis—Fluorouracil—colon cancer	0.000818	0.00814	CcSEcCtD
Norethindrone—Photosensitivity—Fluorouracil—colon cancer	0.000807	0.00802	CcSEcCtD
Norethindrone—Embolism—Methotrexate—colon cancer	0.000791	0.00786	CcSEcCtD
Norethindrone—Renal impairment—Irinotecan—colon cancer	0.000777	0.00773	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Irinotecan—colon cancer	0.000764	0.0076	CcSEcCtD
Norethindrone—Pain in extremity—Vincristine—colon cancer	0.000759	0.00755	CcSEcCtD
Norethindrone—Pulmonary embolism—Capecitabine—colon cancer	0.000682	0.00678	CcSEcCtD
Norethindrone—Abdominal distension—Irinotecan—colon cancer	0.000644	0.0064	CcSEcCtD
Norethindrone—Photosensitivity reaction—Vincristine—colon cancer	0.000599	0.00596	CcSEcCtD
Norethindrone—Depression—Vincristine—colon cancer	0.000584	0.0058	CcSEcCtD
Norethindrone—Acute coronary syndrome—Vincristine—colon cancer	0.000577	0.00574	CcSEcCtD
Norethindrone—Myocardial infarction—Vincristine—colon cancer	0.000574	0.00571	CcSEcCtD
Norethindrone—Thrombophlebitis—Capecitabine—colon cancer	0.000572	0.00569	CcSEcCtD
Norethindrone—Photosensitivity—Capecitabine—colon cancer	0.000564	0.00561	CcSEcCtD
Norethindrone—Acute coronary syndrome—Irinotecan—colon cancer	0.000562	0.00559	CcSEcCtD
Norethindrone—Renal failure—Irinotecan—colon cancer	0.00056	0.00557	CcSEcCtD
Norethindrone—Photosensitivity reaction—Fluorouracil—colon cancer	0.000559	0.00556	CcSEcCtD
Norethindrone—Myocardial infarction—Irinotecan—colon cancer	0.000559	0.00556	CcSEcCtD
Norethindrone—PGR—epithelium—colon cancer	0.000541	0.0514	CbGeAlD
Norethindrone—Acute coronary syndrome—Fluorouracil—colon cancer	0.000538	0.00535	CcSEcCtD
Norethindrone—Myocardial infarction—Fluorouracil—colon cancer	0.000535	0.00532	CcSEcCtD
Norethindrone—PGR—smooth muscle tissue—colon cancer	0.000522	0.0495	CbGeAlD
Norethindrone—Renal impairment—Capecitabine—colon cancer	0.00052	0.00517	CcSEcCtD
Norethindrone—Connective tissue disorder—Vincristine—colon cancer	0.000516	0.00513	CcSEcCtD
Norethindrone—Haemoglobin—Irinotecan—colon cancer	0.000514	0.00511	CcSEcCtD
Norethindrone—Purpura—Capecitabine—colon cancer	0.000514	0.00511	CcSEcCtD
Norethindrone—Haemorrhage—Irinotecan—colon cancer	0.000512	0.00509	CcSEcCtD
Norethindrone—Pulmonary embolism—Methotrexate—colon cancer	0.000508	0.00505	CcSEcCtD
Norethindrone—CYP3A7—liver—colon cancer	0.000507	0.0482	CbGeAlD
Norethindrone—Connective tissue disorder—Irinotecan—colon cancer	0.000503	0.005	CcSEcCtD
Norethindrone—Pain in extremity—Capecitabine—colon cancer	0.000495	0.00492	CcSEcCtD
Norethindrone—Haemoglobin—Fluorouracil—colon cancer	0.000493	0.0049	CcSEcCtD
Norethindrone—Haemorrhage—Fluorouracil—colon cancer	0.00049	0.00487	CcSEcCtD
Norethindrone—Migraine—Capecitabine—colon cancer	0.000487	0.00485	CcSEcCtD
Norethindrone—Mood swings—Capecitabine—colon cancer	0.000469	0.00466	CcSEcCtD
Norethindrone—Alopecia—Vincristine—colon cancer	0.000464	0.00462	CcSEcCtD
Norethindrone—Immune system disorder—Irinotecan—colon cancer	0.000462	0.0046	CcSEcCtD
Norethindrone—Mental disorder—Vincristine—colon cancer	0.00046	0.00458	CcSEcCtD
Norethindrone—Alopecia—Irinotecan—colon cancer	0.000452	0.0045	CcSEcCtD
Norethindrone—Breast disorder—Capecitabine—colon cancer	0.000447	0.00445	CcSEcCtD
Norethindrone—Flatulence—Irinotecan—colon cancer	0.000439	0.00436	CcSEcCtD
Norethindrone—Alopecia—Fluorouracil—colon cancer	0.000433	0.00431	CcSEcCtD
Norethindrone—CYP3A7-CYP3A51P—liver—colon cancer	0.000431	0.0409	CbGeAlD
Norethindrone—Abdominal distension—Capecitabine—colon cancer	0.000431	0.00428	CcSEcCtD
Norethindrone—Thrombophlebitis—Methotrexate—colon cancer	0.000426	0.00423	CcSEcCtD
Norethindrone—SHBG—bone marrow—colon cancer	0.000422	0.04	CbGeAlD
Norethindrone—Photosensitivity—Methotrexate—colon cancer	0.00042	0.00417	CcSEcCtD
Norethindrone—PGR—lymphoid tissue—colon cancer	0.000417	0.0396	CbGeAlD
Norethindrone—SHBG—vagina—colon cancer	0.000404	0.0383	CbGeAlD
Norethindrone—Convulsion—Vincristine—colon cancer	0.000396	0.00394	CcSEcCtD
Norethindrone—Photosensitivity reaction—Capecitabine—colon cancer	0.000391	0.00388	CcSEcCtD
Norethindrone—Weight increased—Capecitabine—colon cancer	0.000389	0.00387	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Methotrexate—colon cancer	0.000381	0.00379	CcSEcCtD
Norethindrone—Depression—Capecitabine—colon cancer	0.00038	0.00378	CcSEcCtD
Norethindrone—Acute coronary syndrome—Capecitabine—colon cancer	0.000376	0.00374	CcSEcCtD
Norethindrone—Renal failure—Capecitabine—colon cancer	0.000375	0.00373	CcSEcCtD
Norethindrone—Myocardial infarction—Capecitabine—colon cancer	0.000374	0.00372	CcSEcCtD
Norethindrone—Oedema—Vincristine—colon cancer	0.000373	0.00371	CcSEcCtD
Norethindrone—Anaphylactic shock—Vincristine—colon cancer	0.000373	0.00371	CcSEcCtD
Norethindrone—Convulsion—Fluorouracil—colon cancer	0.00037	0.00368	CcSEcCtD
Norethindrone—PGR—vagina—colon cancer	0.000364	0.0345	CbGeAlD
Norethindrone—Anaphylactic shock—Irinotecan—colon cancer	0.000364	0.00362	CcSEcCtD
Norethindrone—Oedema—Irinotecan—colon cancer	0.000364	0.00362	CcSEcCtD
Norethindrone—Hepatobiliary disease—Capecitabine—colon cancer	0.000361	0.00359	CcSEcCtD
Norethindrone—Mood swings—Methotrexate—colon cancer	0.000349	0.00347	CcSEcCtD
Norethindrone—Oedema—Fluorouracil—colon cancer	0.000348	0.00346	CcSEcCtD
Norethindrone—Anaphylactic shock—Fluorouracil—colon cancer	0.000348	0.00346	CcSEcCtD
Norethindrone—Haemoglobin—Capecitabine—colon cancer	0.000344	0.00342	CcSEcCtD
Norethindrone—ABCB1—blood vessel—colon cancer	0.000344	0.0326	CbGeAlD
Norethindrone—Haemorrhage—Capecitabine—colon cancer	0.000342	0.00341	CcSEcCtD
Norethindrone—Hepatitis—Capecitabine—colon cancer	0.000342	0.00341	CcSEcCtD
Norethindrone—SHBG—liver—colon cancer	0.000341	0.0324	CbGeAlD
Norethindrone—Insomnia—Vincristine—colon cancer	0.000338	0.00336	CcSEcCtD
Norethindrone—Connective tissue disorder—Capecitabine—colon cancer	0.000337	0.00335	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—colon cancer	0.000333	0.00331	CcSEcCtD
Norethindrone—Insomnia—Irinotecan—colon cancer	0.000329	0.00327	CcSEcCtD
Norethindrone—Erythema multiforme—Capecitabine—colon cancer	0.000324	0.00322	CcSEcCtD
Norethindrone—Somnolence—Irinotecan—colon cancer	0.000323	0.00321	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Vincristine—colon cancer	0.000322	0.0032	CcSEcCtD
Norethindrone—Fatigue—Vincristine—colon cancer	0.000322	0.0032	CcSEcCtD
Norethindrone—Dyspepsia—Irinotecan—colon cancer	0.00032	0.00318	CcSEcCtD
Norethindrone—Insomnia—Fluorouracil—colon cancer	0.000315	0.00313	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Irinotecan—colon cancer	0.000314	0.00312	CcSEcCtD
Norethindrone—Fatigue—Irinotecan—colon cancer	0.000313	0.00312	CcSEcCtD
Norethindrone—Somnolence—Fluorouracil—colon cancer	0.00031	0.00308	CcSEcCtD
Norethindrone—Immune system disorder—Capecitabine—colon cancer	0.000309	0.00308	CcSEcCtD
Norethindrone—Dyspepsia—Fluorouracil—colon cancer	0.000306	0.00305	CcSEcCtD
Norethindrone—Gastrointestinal pain—Vincristine—colon cancer	0.000305	0.00304	CcSEcCtD
Norethindrone—CYP2C19—digestive system—colon cancer	0.000304	0.0289	CbGeAlD
Norethindrone—Alopecia—Capecitabine—colon cancer	0.000303	0.00301	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000301	0.00299	CcSEcCtD
Norethindrone—Mental disorder—Capecitabine—colon cancer	0.0003	0.00298	CcSEcCtD
Norethindrone—Gastrointestinal pain—Irinotecan—colon cancer	0.000297	0.00296	CcSEcCtD
Norethindrone—Abdominal pain—Vincristine—colon cancer	0.000295	0.00293	CcSEcCtD
Norethindrone—Flatulence—Capecitabine—colon cancer	0.000294	0.00292	CcSEcCtD
Norethindrone—CYP3A5—renal system—colon cancer	0.000292	0.0277	CbGeAlD
Norethindrone—Photosensitivity reaction—Methotrexate—colon cancer	0.000291	0.00289	CcSEcCtD
Norethindrone—Abdominal pain—Irinotecan—colon cancer	0.000287	0.00286	CcSEcCtD
Norethindrone—Drowsiness—Methotrexate—colon cancer	0.000284	0.00282	CcSEcCtD
Norethindrone—Depression—Methotrexate—colon cancer	0.000283	0.00282	CcSEcCtD
Norethindrone—ALB—liver—colon cancer	0.000281	0.0267	CbGeAlD
Norethindrone—Renal failure—Methotrexate—colon cancer	0.000279	0.00278	CcSEcCtD
Norethindrone—Urticaria—Fluorouracil—colon cancer	0.000277	0.00275	CcSEcCtD
Norethindrone—Hypersensitivity—Vincristine—colon cancer	0.000275	0.00273	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—colon cancer	0.000269	0.00267	CcSEcCtD
Norethindrone—CYP2C19—vagina—colon cancer	0.000269	0.0255	CbGeAlD
Norethindrone—Hypersensitivity—Irinotecan—colon cancer	0.000268	0.00266	CcSEcCtD
Norethindrone—Asthenia—Vincristine—colon cancer	0.000268	0.00266	CcSEcCtD
Norethindrone—Asthenia—Irinotecan—colon cancer	0.000261	0.00259	CcSEcCtD
Norethindrone—Hypersensitivity—Fluorouracil—colon cancer	0.000257	0.00255	CcSEcCtD
Norethindrone—Haemoglobin—Methotrexate—colon cancer	0.000256	0.00255	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—colon cancer	0.000255	0.00254	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—colon cancer	0.000255	0.00254	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000252	0.00251	CcSEcCtD
Norethindrone—Dizziness—Vincristine—colon cancer	0.000247	0.00245	CcSEcCtD
Norethindrone—Pruritus—Fluorouracil—colon cancer	0.000246	0.00245	CcSEcCtD
Norethindrone—Oedema—Capecitabine—colon cancer	0.000243	0.00242	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—colon cancer	0.000241	0.0024	CcSEcCtD
Norethindrone—Dizziness—Irinotecan—colon cancer	0.00024	0.00239	CcSEcCtD
Norethindrone—CYP3A5—digestive system—colon cancer	0.00024	0.0227	CbGeAlD
Norethindrone—Vomiting—Vincristine—colon cancer	0.000237	0.00236	CcSEcCtD
Norethindrone—Skin disorder—Capecitabine—colon cancer	0.000236	0.00235	CcSEcCtD
Norethindrone—Rash—Vincristine—colon cancer	0.000235	0.00234	CcSEcCtD
Norethindrone—PGR—lymph node—colon cancer	0.000235	0.0223	CbGeAlD
Norethindrone—Dermatitis—Vincristine—colon cancer	0.000235	0.00234	CcSEcCtD
Norethindrone—Headache—Vincristine—colon cancer	0.000234	0.00233	CcSEcCtD
Norethindrone—Vomiting—Irinotecan—colon cancer	0.000231	0.0023	CcSEcCtD
Norethindrone—Immune system disorder—Methotrexate—colon cancer	0.00023	0.00229	CcSEcCtD
Norethindrone—Dizziness—Fluorouracil—colon cancer	0.00023	0.00229	CcSEcCtD
Norethindrone—Rash—Irinotecan—colon cancer	0.000229	0.00228	CcSEcCtD
Norethindrone—Dermatitis—Irinotecan—colon cancer	0.000229	0.00228	CcSEcCtD
Norethindrone—Headache—Irinotecan—colon cancer	0.000228	0.00226	CcSEcCtD
Norethindrone—CYP2C19—liver—colon cancer	0.000227	0.0215	CbGeAlD
Norethindrone—Alopecia—Methotrexate—colon cancer	0.000225	0.00224	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—colon cancer	0.000223	0.00222	CcSEcCtD
Norethindrone—Nausea—Vincristine—colon cancer	0.000222	0.0022	CcSEcCtD
Norethindrone—Vomiting—Fluorouracil—colon cancer	0.000221	0.0022	CcSEcCtD
Norethindrone—Insomnia—Capecitabine—colon cancer	0.00022	0.00219	CcSEcCtD
Norethindrone—Rash—Fluorouracil—colon cancer	0.00022	0.00218	CcSEcCtD
Norethindrone—Dermatitis—Fluorouracil—colon cancer	0.000219	0.00218	CcSEcCtD
Norethindrone—CYP3A4—renal system—colon cancer	0.000219	0.0208	CbGeAlD
Norethindrone—Headache—Fluorouracil—colon cancer	0.000218	0.00217	CcSEcCtD
Norethindrone—Nausea—Irinotecan—colon cancer	0.000216	0.00215	CcSEcCtD
Norethindrone—ALB—lymph node—colon cancer	0.000216	0.0205	CbGeAlD
Norethindrone—Dyspepsia—Capecitabine—colon cancer	0.000214	0.00213	CcSEcCtD
Norethindrone—CYP3A5—vagina—colon cancer	0.000212	0.0201	CbGeAlD
Norethindrone—Gastrointestinal disorder—Capecitabine—colon cancer	0.00021	0.00209	CcSEcCtD
Norethindrone—Fatigue—Capecitabine—colon cancer	0.00021	0.00209	CcSEcCtD
Norethindrone—Nausea—Fluorouracil—colon cancer	0.000207	0.00206	CcSEcCtD
Norethindrone—ABCB1—embryo—colon cancer	0.000205	0.0195	CbGeAlD
Norethindrone—Gastrointestinal pain—Capecitabine—colon cancer	0.000199	0.00198	CcSEcCtD
Norethindrone—Urticaria—Capecitabine—colon cancer	0.000193	0.00192	CcSEcCtD
Norethindrone—Abdominal pain—Capecitabine—colon cancer	0.000192	0.00191	CcSEcCtD
Norethindrone—Convulsion—Methotrexate—colon cancer	0.000192	0.00191	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000188	0.00187	CcSEcCtD
Norethindrone—Anaphylactic shock—Methotrexate—colon cancer	0.000181	0.0018	CcSEcCtD
Norethindrone—CYP3A4—digestive system—colon cancer	0.00018	0.0171	CbGeAlD
Norethindrone—Hypersensitivity—Capecitabine—colon cancer	0.000179	0.00178	CcSEcCtD
Norethindrone—CYP3A5—liver—colon cancer	0.000178	0.0169	CbGeAlD
Norethindrone—Skin disorder—Methotrexate—colon cancer	0.000176	0.00175	CcSEcCtD
Norethindrone—Asthenia—Capecitabine—colon cancer	0.000175	0.00174	CcSEcCtD
Norethindrone—Pruritus—Capecitabine—colon cancer	0.000172	0.00171	CcSEcCtD
Norethindrone—ABCB1—epithelium—colon cancer	0.000167	0.0159	CbGeAlD
Norethindrone—Insomnia—Methotrexate—colon cancer	0.000164	0.00163	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—colon cancer	0.000161	0.0016	CcSEcCtD
Norethindrone—Dizziness—Capecitabine—colon cancer	0.000161	0.0016	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—colon cancer	0.000159	0.00159	CcSEcCtD
Norethindrone—Drospirenone—PTGS2—colon cancer	0.000158	0.381	CrCbGaD
Norethindrone—Gastrointestinal disorder—Methotrexate—colon cancer	0.000156	0.00156	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—colon cancer	0.000156	0.00155	CcSEcCtD
Norethindrone—ABCB1—renal system—colon cancer	0.000155	0.0147	CbGeAlD
Norethindrone—Vomiting—Capecitabine—colon cancer	0.000155	0.00154	CcSEcCtD
Norethindrone—Rash—Capecitabine—colon cancer	0.000153	0.00153	CcSEcCtD
Norethindrone—Dermatitis—Capecitabine—colon cancer	0.000153	0.00152	CcSEcCtD
Norethindrone—Headache—Capecitabine—colon cancer	0.000152	0.00152	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—colon cancer	0.000148	0.00147	CcSEcCtD
Norethindrone—Nausea—Capecitabine—colon cancer	0.000145	0.00144	CcSEcCtD
Norethindrone—Urticaria—Methotrexate—colon cancer	0.000144	0.00143	CcSEcCtD
Norethindrone—Abdominal pain—Methotrexate—colon cancer	0.000143	0.00142	CcSEcCtD
Norethindrone—CYP3A4—liver—colon cancer	0.000134	0.0127	CbGeAlD
Norethindrone—Hypersensitivity—Methotrexate—colon cancer	0.000133	0.00133	CcSEcCtD
Norethindrone—Asthenia—Methotrexate—colon cancer	0.00013	0.00129	CcSEcCtD
Norethindrone—ABCB1—lymphoid tissue—colon cancer	0.000129	0.0122	CbGeAlD
Norethindrone—Pruritus—Methotrexate—colon cancer	0.000128	0.00127	CcSEcCtD
Norethindrone—ABCB1—digestive system—colon cancer	0.000127	0.0121	CbGeAlD
Norethindrone—Dizziness—Methotrexate—colon cancer	0.00012	0.00119	CcSEcCtD
Norethindrone—ABCB1—bone marrow—colon cancer	0.000117	0.0111	CbGeAlD
Norethindrone—Vomiting—Methotrexate—colon cancer	0.000115	0.00115	CcSEcCtD
Norethindrone—Rash—Methotrexate—colon cancer	0.000114	0.00114	CcSEcCtD
Norethindrone—Dermatitis—Methotrexate—colon cancer	0.000114	0.00113	CcSEcCtD
Norethindrone—Headache—Methotrexate—colon cancer	0.000113	0.00113	CcSEcCtD
Norethindrone—ABCB1—vagina—colon cancer	0.000112	0.0107	CbGeAlD
Norethindrone—Nausea—Methotrexate—colon cancer	0.000108	0.00107	CcSEcCtD
Norethindrone—ABCB1—liver—colon cancer	9.48e-05	0.009	CbGeAlD
Norethindrone—Ethinyl Estradiol—ABCB1—colon cancer	9.26e-05	0.223	CrCbGaD
Norethindrone—ABCB1—lymph node—colon cancer	7.27e-05	0.0069	CbGeAlD
Norethindrone—Hydrocortisone—ABCB1—colon cancer	6.37e-05	0.153	CrCbGaD
Norethindrone—Progesterone—ABCB1—colon cancer	5.19e-05	0.125	CrCbGaD
Norethindrone—Testosterone—ABCB1—colon cancer	4.9e-05	0.118	CrCbGaD
